
Brian Gormley
Special Writer at The Wall Street Journal
Special Writer at Dow Jones Newswires
Articles
-
6 days ago |
wsj.com | Brian Gormley
Western drugmakers, investors increasingly aim to acquire Chinese compoundsMay 29, 2025 6:00 am ET|WSJ ProU.S. venture capitalists are racing to tap in to China’s growing biotechnology prowess, a shift moving the industry into a more global market for the most promising new drug candidates. Several licensing pacts between Western and Chinese drugmakers have marked China’s emergence in biotech, a rise decades in the making.
-
2 weeks ago |
wsj.com | Brian Gormley
The NYSE debut is the first major IPO for a venture-backed digital-health company since the pandemic-era boomMay 22, 2025 7:33 pm ET|WSJ ProShares of Hinge Health jumped on their first day of trading on the New York Stock Exchange, giving a much-needed win to a digital-health industry that’s been starved of initial public offerings.
-
1 month ago |
venturecapital.createsend1.com | Brian Gormley
Good day. Startup Creyon Bio has formed a collaboration with drugmaker Eli Lilly that could be worth more than $1 billion, the companies say. Creyon, whose investors include DCVC Bio and Lux Capital, has technology capable of designing oligonucleotides, or short nucleic-acid sequences, that could be used to treat a range of diseases.
-
1 month ago |
createsend.com | Brian Gormley
Good day. Startup Creyon Bio has formed a collaboration with drugmaker Eli Lilly that could be worth more than $1 billion, the companies say. Creyon, whose investors include DCVC Bio and Lux Capital, has technology capable of designing oligonucleotides, or short nucleic-acid sequences, that could be used to treat a range of diseases.
-
1 month ago |
venturecapital.cmail19.com | Brian Gormley
Good day. Startup Creyon Bio has formed a collaboration with drugmaker Eli Lilly that could be worth more than $1 billion, the companies say. Creyon, whose investors include DCVC Bio and Lux Capital, has technology capable of designing oligonucleotides, or short nucleic-acid sequences, that could be used to treat a range of diseases.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →